Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Tuesday, April 25, 2017
 
Recommended for you
FDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller
Fortune Magazine • Sy Mukherjee
Johnson And Johnson: Seize It
Seeking Alpha • Quad 7 Capital
Johnson & Johnson: Modest Price Decline Presents Buying Opportunity
Seeking Alpha • Sure Dividend
Samsung Bioepis wins FDA approval for rheumatoid arthritis drug
CNBC
FDA approves Merck biosimilar for immune-disorder drug Renflexis
Seeking Alpha • Jason Aycock
Johnson & Johnson: Need Rock-Solid Dividend Growth? Look Here
Seeking Alpha • Josh Arnold
Johnson & Johnson Wants to Use 3D Printing to Heal Broken Bones
Fortune Magazine • Sy Mukherjee
Johnson & Johnson: Was The Sell-Off Justified?
Seeking Alpha • Josh Arnold
Johnson & Johnson: Was The Sell-Off Justified?
Seeking Alpha
Johnson & Johnson: Not Too Late To Take Chips Off The Table
Seeking Alpha • Casey Hoerth
 
Recommended for You
Johnson & Johnson, Merck & Co., Inc.
FDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller
Fortune MagazineSy Mukherjee
Pharma giant Johnson & Johnson's Remicade brought in nearly $7 billion in sales last year. But Samsung Bioepis and partner Merck are hoping to claw away some of that market share with a new rival therapy—one that could come at a significant...
Share
Actelion Pharmaceuticals, Health Finance
Johnson And Johnson: Seize It
Seeking AlphaQuad 7 Capital
Summary You won't become an overnight millionaire in this name. Q1 earnings are out. The quarter was uninspiring but a new acquisition provides a boost to the outlook. Johnson & Johnson (NYSE:JNJ) is a name I continue to be bullish on long-term...
Share
Actelion Pharmaceuticals, Finance
Johnson & Johnson: Modest Price Decline Presents Buying Opportunity
Seeking AlphaSure Dividend
Written by Nicholas McCullum for Sure Dividend on April 21, 2017. Johnson & Johnson (NYSE:JNJ) is one of the most stable businesses around. The company’s statistics are impressive: 33 years of consecutive earnings-per-share growth (currency-adjusted) The lowest stock price volatility of any...
Share
Biotechnology, Johnson & Johnson
Samsung Bioepis wins FDA approval for rheumatoid arthritis drug
CNBC
Samsung Bioepis has won U.S. regulatory approval for key biosimilar drug.
Share
Johnson & Johnson, Merck & Co., Inc.
FDA approves Merck biosimilar for immune-disorder drug Renflexis
Seeking AlphaJason Aycock
The FDA has approved Renflexis, a second near-copy of Remicade, used for rheumatoid arthritis and other immune system disorders. Merck (MRK -1.1%) will market the drug, developed by South Korea's Samsung Bioepis, and says it should be available in six months (a...
Share
Actelion Pharmaceuticals, Finance
Johnson & Johnson: Need Rock-Solid Dividend Growth? Look Here
Seeking AlphaJosh Arnold
Summary JNJ has a very strong track record of dividend growth. Mid- to high single digit increases have become the norm. But more importantly, JNJ can afford to continue to finance these raises for years to come without the benefit of higher...
Share
Johnson & Johnson
Johnson & Johnson Wants to Use 3D Printing to Heal Broken Bones
Fortune MagazineSy Mukherjee
It just acquired new 3D printing tech.
Share
Actelion Pharmaceuticals, Johnson & Johnson
Johnson & Johnson: Was The Sell-Off Justified?
Seeking AlphaJosh Arnold
Summary JNJ's Q1 revenue came in light. But margin expansion is alive and well and that is enormously important. The stock still looks reasonably valued to me, however, as Q1 wasn't bad enough to warrant a sell-off. Johnson & Johnson (NYSE:JNJ) is...
Share
Health Finance, Johnson & Johnson
Johnson & Johnson: Was The Sell-Off Justified?
Seeking Alpha
Share
Johnson & Johnson
Johnson & Johnson: Not Too Late To Take Chips Off The Table
Seeking AlphaCasey Hoerth
Summary Shares of J&J slipped over 3% on Tuesday. Since an article I wrote back on July 25th, shares have dropped, but then climbed to new highs. Overall, it's not too late to take some chips off the table here. Back on...
Share